Mylan Recalls Doxorubicin Vials Due to Potential Mispackaging
Mylan Institutional LLC is recalling 936 vials of Doxorubicin Hydrochloride Injection because they may have been mispackaged with Ifosfamide Injection.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Mylan Institutional LLC is recalling 936 vials of Doxorubicin Hydrochloride Injection, USP, 200 mg/100 mL (2 mg/mL). The recall is due to a mispackaging error where correctly labeled vials of Ifosfamide Injection 50 mg/mL, 60 mL may have been packaged in cartons labeled for Doxorubicin Hydrochloride Injection.
The affected product is identified by Lot Number 7801009 and has an expiration date of April 2015. The product was distributed nationwide. The recall is classified as Class III by the FDA, indicating that use of or exposure to the violative product is not likely to cause adverse health consequences.
Healthcare providers and patients should check their inventory for this specific lot number and contact Mylan Institutional LLC for further instructions on how to return the product.
The recalled product
- Product
- DOXOrubicin Hydrochloride Injection, USP, 200 mg/100 mL (2 mg/mL), For IV Use Only, Sterile, ISOTONIC SOLUTION, Caution: Cytotoxic Agent, 100 mL Multi-Dose Vial, Rx Only, Manufactured By: Onco Therapies Limited, Bangalore, 560105, INDIA, Distributed By: Amneal-Agila, LLC, Glasgow
- Manufacturer
- Mylan Institutional LLC
- Category
- Drug — Injection
- Affected units
- 936
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot Number: 7801009
- Exp: Apr-2015
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Mylan Institutional LLC
See all →- LowThiamine HCl Injection Recall: Vials with Incorrect Lot Numbers
FDA (Drugs) · 2021-06-09
- CriticalMylan Recalls Tranexamic Acid Injection Due to Labeling Mix-Up
FDA (Drugs) · 2020-09-09
- CriticalMylan Recalls Amiodarone Hydrochloride Injection Due to Labeling Mix-Up
FDA (Drugs) · 2020-09-09
- SevereMylan Recalls Daptomycin Injection Due to Particulate Matter
FDA (Drugs) · 2020-08-12
- ModerateMylan Recalls Aloprim Injection Vials Due to Discoloration
FDA (Drugs) · 2020-05-27
Same hazard · mis labeling
See all →- ModerateMedline Trach Tube Kit Recalled for Component Labeling Discrepancy
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateOlympus Recalls PowerSeal Sealer Due to Incorrect Outer Box Labeling
FDA (Devices) · 2026-09-02
- HighSura Tanmen Ramen Noodles Recalled for Undeclared Fish Allergens
FDA (Food) · 2026-09-02
- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-09-02